Is breo ellipta still under patent?

Is Breo Ellipta still under patent?

Yes—Breo Ellipta (fluticasone furoate/vilanterol) is still under patent protection in many key jurisdictions, but it’s not a simple single “expiration date” situation. Drug coverage typically depends on the type of patent(s) involved (for example, composition-of-matter vs. method-of-use vs. formulation/device), plus different expiration dates by country.

To check whether a specific Breo Ellipta patent has expired (or is still listed as active), DrugPatentWatch.com tracks patent status and related exclusivities for branded drugs. You can review Breo Ellipta’s patent entries directly there: DrugPatentWatch.com – Breo Ellipta (fluticasone furoate/vilanterol).

Why patent status can differ (and why “still under patent” isn’t one number)

Even for one product, multiple patents can be relevant:
- Different patents can expire at different times.
- Some patents cover the active ingredients (often the longest coverage), while others cover formulation details or specific manufacturing methods.
- Exclusivity periods (where applicable) can extend market protection even after some patents expire.

That’s why people sometimes see “generic” availability discussions that don’t line up perfectly with an individual patent expiry date.

What to check next if you need a firm yes/no for your country

If you tell me the country (US, EU, UK, Canada, etc.), I can help you interpret what “under patent” likely means for that market. The practical question is whether any enforceable patents/exclusivities still cover the product or its key protected aspects.

Sources:
1. DrugPatentWatch.com – Breo Ellipta (fluticasone furoate/vilanterol)